RGNX | REGENXBIO Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	9.02 - 9.72
52 Week Range	5.04 - 17.52
Beta	1.50
Implied Volatility	652.49%
IV Rank	47.81%
Day's Volume	559,812
Average Volume	962,513
Shares Outstanding	50,116,900
Market Cap	481,623,409
Sector	Healthcare
Industry	Biotechnology
IPO Date	2015-09-17

Valuation
Profitability
Growth
Health
P/E Ratio	-2.09
Forward P/E Ratio	-6.85
EPS	-4.59
1YR Price Target	57.50
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	344
Country	USA
Website	RGNX

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa).

RGNX's peers: ABEO, ACIU, CLLS, CRNX, KRYS, QURE, RCKT, DAWN, REPL, MIRM, RNA, PTGX, PLRX, IMCR, RVMD, GLUE, STOK, ANTX, PASG, FDMT, LIAN, KZR, VCEL, IVVD

*Chart delayed

Analyzing fundamentals for RGNX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see RGNX Fundamentals page.

Watching at RGNX technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on RGNX Technicals page.